Direct measurement for the therapies that matter most.

The reason most adherence platforms infer is that direct measurement is hard. Inference is cheap, scalable, and good enough when the dose taken does not need to be known precisely. We have spent our careers on the therapies where it does — as sponsors of clinical trials, as physicians and pharmacists, as researchers in adherence science — and we built Sensal for them.

Biologics, complex topicals, narrow therapeutic index drugs, controlled substances, pediatric formulations, and medications in oncology, dermatology, and CNS care share a property: the difference between something was dispensed and the correct quantity was dispensed is the difference between a therapy that works, a therapy that fails silently, and in some cases a therapy that harms. Proxy signals do not resolve that difference.

Sensal’s platform — Smart Dock for oral solids and non-tube topicals, Smart Cap for tubes — measures quantity dispensed at the point of use, across both delivery formats. To our knowledge no other platform captures this signal across both. The hardware took longer and cost more than a software-only adherence product would have. We took that path because the therapies that matter most cannot be served well by anything less, and because the clinicians, sponsors, and payers responsible for those therapies have been asking for measurement they can act on rather than measurement they have to caveat.